Surgical Resection Outcomes in Patients With Brain Metastasis

Brain Metastases Clinical Trial

Official title:

Prognostic Factors Impacting Surgical Resection Outcomes in Patients With Brain

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06318065
• Other study ID #: B-ER111-370
• Status: Recruiting
• Start date: January 1, 2010
• Est. completion date: September 1, 2024

Study information

• Verified date: February 2024
• Source: National Cheng-Kung University Hospital
• Contact: Jung-Shun Lee, M.D.
• Phone: 886-6-2353535
• Email: nslee1218[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

While many studies have investigated the prognostic factors for patients undergoing surgical resection for primary brain tumors, decision-making for patients with brain metastasis (BM) is more complex because of their higher burden of comorbidities compared to those with primary brain tumors. In addition, although various prognostic indicators have been identified to predict prognosis in several types of cancer, such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), and systemic immune-inflammation index (SII), limited studies have yet determined which group of patients would yield beater survival outcome after surgical resection for BM. This study aimed to investigate the impact of patient and perioperative characteristics and prognostic indicators on survival outcome of patients undergoing surgical resection of BM.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: September 1, 2024
• Est. primary completion date: June 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. patients with Clinical diagnosis of brain metastasis

2. patients who underwent craniotomy surgery for brain metastasis

Exclusion Criteria:

1. patients with insufficient data for associated factors

2. patients who underwent stereotactic biopsy for brain metastasis

3. patients who did not undergo craniotomy surgery for brain metastasis

Related Conditions & MeSH terms

• Brain Metastases
• Brain Neoplasms
• Neoplasm Metastasis

Locations

Country	Name	City	State
Taiwan	Jung-Shun Lee	Tainan	None Selected

Sponsors (1)

Lead Sponsor	Collaborator
National Cheng-Kung University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	survival outcome of patients undergoing surgery for brain metastasis	overall survival of patients	From date of surgery until the date of death from any cause, whichever came first, assessed up to 100 months
Primary	Functional outcome of patients undergoing surgery for brain metastasis	change of preoperative and postoperative modified rankin scale	from date of surgery until 6 months after surgery ordate of death from any cause, whichever came first